Not everyone responds to the first depression treatment they try. It can feel discouraging, like maybe the diagnosis is wrong, or like you’re somehow the problem. But hitting a wall with an initial medication or therapy approach doesn’t mean treatment has failed. It means the process is still unfolding.
This article walks through what happens after that first attempt falls short: how clinicians evaluate what’s working, how they adjust the plan, and what advanced options like ketamine treatment can look like within a broader, evolving psychiatric treatment strategy.
Quick Answer Summary
When first-line depression treatments like medication or therapy are not effective, clinicians carefully evaluate treatment response using symptom tracking and functional measures. Before escalating care, they often adjust dosage, switch medications, or use augmentation strategies. If multiple treatments fail, the condition may be classified as treatment-resistant depression, leading to consideration of advanced options such as TMS or ketamine therapy. This process is structured, collaborative, and designed to find the most effective personalized treatment plan.
How Clinicians Evaluate Treatment Response
Before changing anything, a clinician needs to understand exactly what “not working” means because that answer shapes everything that follows. Depression doesn’t always respond in an all-or-nothing way, and clinicians track that carefully.
Evaluation usually involves a combination of symptom tracking, standardized tools like the PHQ-9 (a nine-question scale that measures depression severity), and a look at functional change, meaning, how is this person doing in daily life? Sleep, concentration, energy, relationships matter. A PHQ-9 score is useful, but it’s one data point among many.
From there, clinicians typically categorize the outcome into three buckets:
- Partial response: Some symptoms improved, but not enough
- Non-response: There was little to no meaningful change
- Intolerable side effects: Medication may have technically done something, but the person couldn’t sustain it
Timing is also a factor. Antidepressants generally need four to eight weeks at an adequate dose before a clinician can draw conclusions. Therefore, calling something a “failure” before it has had a real chance to work would lead to premature changes that don’t help.
Adjusting the Current Plan Before Moving On
When the first approach isn’t producing enough change, the next step usually isn’t a dramatic overhaul. It’s iteration. Clinicians tend to make deliberate, targeted adjustments before escalating to something entirely different.
That might mean raising the dose if a patient is still under the therapeutic threshold. It might mean switching to a different antidepressant within the same class, or moving to a different class altogether. Augmentation is another common route by adding a second agent that can boost the effect of the primary medication rather than replacing it.
This back-and-forth can feel frustrating when you’re in it. But it’s not random. Each adjustment is an attempt to narrow in on what this specific person’s brain responds to. Clinicians often go through several permutations at this stage before determining that the case warrants more intensive intervention. That iteration is a normal part of how depression treatment works, not a sign that you’re running out of options.
Defining Treatment Resistance and Escalating Care
There’s a clinical term for cases where standard approaches keep falling short: treatment-resistant depression, or TRD. The most used definition is an inadequate response to at least two antidepressant trials, each conducted at an adequate dose and for an adequate duration.
When a patient meets that threshold, the conversation about care typically shifts. The VA/DoD Clinical Practice Guideline for Major Depressive Disorder recommends that clinicians consider advanced interventional options at this stage, including repetitive transcranial magnetic stimulation (TMS), ketamine or esketamine, and ECT. These approaches sit alongside standard care in structured U.S. sequencing guidance.
Ketamine treatment is increasingly part of this conversation. TMS is an effective and safe option for MDD, particularly when prior treatments haven’t produced enough improvement. And a comparative study found that among 89 patients who hadn’t responded to at least two antidepressants, adding rTMS to their current medication produced response rates of 38%, compared to 15% among those who simply switched antidepressants. Remission rates followed a similar pattern: 27% versus 5%.
Importantly, TMS in that study wasn’t used in isolation. Patients continued medication and received psychotherapy. That reflects how most advanced psychiatric treatment works in practice: not as a replacement for everything else, but as an additional layer added thoughtfully to a broader plan.
The choice between TMS, ketamine, Spravato, or other interventions depends on several factors, like how urgent the situation is, what symptoms are most prominent, what the patient has already tried, and what they’re willing and able to do.
FDA labeling for TMS devices describes the treatment as appropriate for patients who haven’t achieved satisfactory improvement from prior antidepressants, which tracks with how clinicians use it in the field.
What Patients Can Expect During This Process
One thing that gets lost in clinical descriptions of escalating care is how collaborative this is. Patients aren’t passive at this stage. Instead, they’re active participants in shaping what happens next.
Regular check-ins are a central part of the process. Clinicians revisit symptoms, side effects, functioning, and goals on an ongoing basis. When advanced options come into the picture, patients are typically walked through what each one involves:
- Time commitment
- What the experience is like
- What outcomes to realistically expect
- How it fits with whatever else is already in the plan
A standard TMS course, for instance, involves daily weekday sessions over four to six weeks, each lasting anywhere from a few minutes to around 40 minutes. That’s a real schedule commitment, and it factors into how clinicians and patients plan together.
Something worth holding onto: When a depression treatment approach isn’t working, that information isn’t a dead end. It’s clinical data. It tells the team something about how this particular person’s depression is behaving, and it guides the next decision more precisely than if there were no prior attempts at all.
“Not working” is not the same as “hopeless.” It’s a narrowing process, even when it doesn’t feel like one.
The goal isn’t to exhaust every option in sequence. The goal is to find the right fit, and increasingly, the range of available psychiatric treatment tools makes that more achievable than it’s ever been.
Let Zeam Help You Navigate What’s Next
If you’ve been through one depression treatment and come out the other side without much to show for it, the question of what comes next can feel heavy. We get that. At Zeam, we’ve worked with a lot of patients who arrived at that exact crossroads, unsure whether to try another medication, curious about ketamine treatment, or just wanting someone to look at their full picture and help them think it through.
Our team in Sacramento, Folsom, and Roseville evaluates where you are in the treatment process, talks through realistic options, including advanced psychiatric treatment approaches like TMS and ketamine, and builds a plan around your situation, not a template. If you’re ready to take that next step, reach out to us today to schedule a consultation.
Key Takeaways
- Not responding to first-line treatment is common – Many patients do not achieve sufficient relief from their first antidepressant or therapy approach, and this is an expected part of care—not a failure.
- Clinicians evaluate response using structured tools – Symptom scales like the PHQ-9, along with functional measures such as sleep, energy, and daily performance, guide treatment decisions.
- Timing matters before declaring treatment failure – Antidepressants typically require 4–8 weeks at an adequate dose before clinicians can determine whether they are effective.¹
- Adjustments are made before escalating care – Clinicians may increase dosage, switch medications, or use augmentation strategies before moving to advanced treatments.¹
- Treatment-resistant depression is clearly defined – Failure to respond to two adequate antidepressant trials is typically considered treatment-resistant depression, guiding next steps.¹
- Advanced treatments are introduced strategically – Options like TMS, ketamine therapy, and ECT are considered when standard approaches are insufficient, based on clinical guidelines.¹
- TMS shows stronger outcomes than medication switching alone – Studies show that adding rTMS can significantly improve response and remission rates compared to switching antidepressants.²
- Advanced treatments are usually combined with existing care – TMS and similar interventions are often used alongside therapy and medication, not as standalone replacements.²
- The process is collaborative and ongoing – Patients actively participate in decisions, with continuous monitoring and adjustments based on real-world outcomes.
Citations
- VA/DoD Clinical Practice Guideline for Major Depressive Disorder
https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/MH/mdd/VADODMDDCPGFinal508.pdf - NEJM Clinician Summary on rTMS for Refractory Depression
https://clinician.nejm.org/repetitive-transcranial-magnetic-stimulation-refractory-depression-nejm-jw.NA58005
